IT202000003733A1 - COLLOIDAL DILUTION FOR TOPICAL AND ORAL USE - Google Patents
COLLOIDAL DILUTION FOR TOPICAL AND ORAL USE Download PDFInfo
- Publication number
- IT202000003733A1 IT202000003733A1 IT102020000003733A IT202000003733A IT202000003733A1 IT 202000003733 A1 IT202000003733 A1 IT 202000003733A1 IT 102020000003733 A IT102020000003733 A IT 102020000003733A IT 202000003733 A IT202000003733 A IT 202000003733A IT 202000003733 A1 IT202000003733 A1 IT 202000003733A1
- Authority
- IT
- Italy
- Prior art keywords
- dilution
- colloidal
- weight
- comprised
- percentage
- Prior art date
Links
- 239000012895 dilution Substances 0.000 title claims description 32
- 238000010790 dilution Methods 0.000 title claims description 32
- 230000000699 topical effect Effects 0.000 title claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- 229920002674 hyaluronan Polymers 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 16
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 12
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 12
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 6
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 229940069338 potassium sorbate Drugs 0.000 claims description 6
- 235000010241 potassium sorbate Nutrition 0.000 claims description 6
- 239000004302 potassium sorbate Substances 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- -1 skin moisturizer Chemical compound 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Description
DESCRIZIONE DESCRIPTION
DILUIZIONE COLLOIDALE PER USO TOPICO ED ORALE COLLOIDAL DILUTION FOR TOPICAL AND ORAL USE
La presente invenzione ha per oggetto una diluizione colloidale comprendete acido ialuronico e metilsulfonilmetano per uso topico ed orale del tipo precisato nel preambolo della prima rivendicazione. The present invention relates to a colloidal dilution comprising hyaluronic acid and methylsulfonylmethane for topical and oral use of the type specified in the preamble of the first claim.
Risulta inoltre oggetto della presente invenzione un preparato medicinale comprendente detta diluizione colloidale. The object of the present invention is also a medicinal preparation comprising said colloidal dilution.
Sono note le raccomandazioni riguardo l?assunzione regolare di acido ialuronico; poich? la durata di vita di una molecola di acido ialuronico ? piuttosto breve, varia da dodici ore a pochi giorni, ne viene consigliata l?assunzione giornaliera per garantire la funzione protettiva, la crescita dei tessuti e l?idratazione cutanea garantite dalla normale presenza di acido ialuronico (e.g. Idratante cutaneo, antiet?, antirughe). The recommendations regarding the regular intake of hyaluronic acid are known; since? the lifespan of a hyaluronic acid molecule? rather short, ranging from twelve hours to a few days, it is recommended to take it daily to ensure the protective function, tissue growth and skin hydration guaranteed by the normal presence of hyaluronic acid (e.g. skin moisturizer, anti-aging, anti-wrinkle).
L?acido ialuronico, rappresentando uno dei principali componenti del tessuto connettivo (macromolecola polisaccaridica della famiglia dei glicosaminoglicani presente in abbondanza nella pelle e nel liquido sinoviale), oltre a risultare uno dei principali responsabili dell?invecchiamento cutaneo, facendo perdere elasticit? e morbidezza alla pelle, pu? agire come coadiuvante nei problemi legati a secchezza della pelle, prurito, rossore, bruciore. Hyaluronic acid, representing one of the main components of the connective tissue (polysaccharide macromolecule of the family of glycosaminoglycans present in abundance in the skin and in the synovial fluid), as well as being one of the main responsible for skin aging, making it lose elasticity? and softness to the skin, pu? act as an adjuvant in problems related to dry skin, itching, redness, burning.
Ancora, lo stesso acido ialuronico, ? utilizzato come film idratante e protettivo con la saliva, depositandosi sulle mucose infiammate di bocca e faringe, favorendo il processo di guarigione delle mucose orali. Again, the same hyaluronic acid,? used as a moisturizing and protective film with saliva, depositing itself on the inflamed mucous membranes of the mouth and pharynx, favoring the healing process of the oral mucosa.
Ancora, essendo in grado di incamerare moltissime molecole d'acqua, l'acido ialuronico ? anche in grado di agire come ammortizzatore di shock meccanici e come efficiente lubrificante (i.e. nel liquido sinoviale), prevenendo il danneggiamento delle cellule del tessuto da stress fisici. Still, being able to store a lot of water molecules, hyaluronic acid? also able to act as a shock absorber for mechanical shocks and as an efficient lubricant (i.e. in the synovial fluid), preventing damage to tissue cells from physical stress.
In pi?, con riferimento ora al metilsulfonilmetano (MSM), esso si lega alle mucose, creando una barriera contro allergeni, parassiti, tossine e radicali liberi. In addition, with reference now to methylsulfonylmethane (MSM), it binds to the mucous membranes, creating a barrier against allergens, parasites, toxins and free radicals.
Generalmente l?MSM pu? essere utilizzato come antinfiammatorio, condroprotettore (riduzione del dolore e dell'infiammazione articolare), promotore di trofismo di pelle e capelli, facilitatore della cicatrizzazione delle ferite e normalizzatore delle funzioni gastro-intestinali Generally the MSM can? be used as an anti-inflammatory, chondroprotector (reduction of pain and joint inflammation), promoter of skin and hair trophism, facilitator of wound healing and normalizer of gastrointestinal functions
La tecnica nota descritta comprende alcuni importanti inconvenienti. The known art described includes some important drawbacks.
In particolare, la composizione e le forme con cui l?acido ialuronico e il metilsulfonilmetano vengono prodotti e commercializzati come prodotti medicali non permettono una rapida ed efficace assunzione di questi principi attivi. In particular, the composition and the forms with which hyaluronic acid and methylsulfonylmethane are produced and marketed as medical products do not allow a rapid and effective intake of these active ingredients.
In questa situazione il compito tecnico alla base della presente invenzione ? ideare una composizione per una diluizione colloidale per uso topico ed orale in grado di ovviare sostanzialmente ad almeno parte degli inconvenienti citati. In this situation, the technical task underlying the present invention? devising a composition for a colloidal dilution for topical and oral use capable of substantially obviating at least part of the aforementioned drawbacks.
Nell'ambito di detto compito tecnico ? un importante scopo dell'invenzione ottenere una diluizione colloidale atta a permettere un rapido ed efficace assorbimento dei principi attivi. As part of this technical task? an important object of the invention is to obtain a colloidal dilution suitable to allow a rapid and effective absorption of the active principles.
Un altro importante scopo dell'invenzione ? realizzare una diluizione colloidale atta ad uso sia topico che cutaneo. Another important purpose of the invention? make a colloidal dilution suitable for both topical and cutaneous use.
In pi? un importante scopo della presente invenzione ? fornire una diluizione colloidale che abbia un effetto idratante, lenitivo ed elasticizzante nei problemi legati a secchezza della pelle ed invecchiamento cutaneo. In addition? an important purpose of the present invention? provide a colloidal dilution that has a moisturizing, soothing and elasticizing effect in problems related to dryness of the skin and skin aging.
Ancora, uno scopo della presente invenzione ? prevedere una diluizione colloidale con effetto antinfiammatorio. Again, an object of the present invention? provide for a colloidal dilution with an anti-inflammatory effect.
Infine, uno scopo della presente invenzione ? prevedere una diluizione colloidale che permetta di reintegrare i deficit di acido ialuronico dovuti alla sua carenza naturale in soggetti di et? avanzata. Finally, a purpose of the present invention? provide for a colloidal dilution that allows to reintegrate the hyaluronic acid deficiency due to its natural deficiency in subjects of age? advanced.
Il compito tecnico e gli scopi specificati sono raggiunti da una diluizione colloidale per uso topico ed orale come rivendicato nella annessa rivendicazione 1. The technical task and the specified aims are achieved by a colloidal dilution for topical and oral use as claimed in the attached claim 1.
Soluzioni tecniche preferite sono evidenziate nelle rivendicazioni dipendenti. Preferred technical solutions are highlighted in the dependent claims.
Nel presente documento, le misure, i valori, le forme e i riferimenti geometrici (come perpendicolarit? e parallelismo), quando associati a parole come "circa" o altri simili termini quali "pressoch?" o "sostanzialmente", sono da intendersi come a meno di errori di misura o imprecisioni dovute a errori di produzione e/o fabbricazione e, soprattutto, a meno di un lieve scostamento dal valore, dalla misura, dalla forma o riferimento geometrico cui ? associato. Ad esempio, tali termini, se associati a un valore, indicano preferibilmente uno scostamento non superiore al 10% del valore stesso. In this document, measurements, values, shapes and geometric references (such as perpendicularity and parallelism), when associated with words such as "about" or other similar terms such as "almost" or "substantially", are to be understood as unless there are measurement errors or inaccuracies due to production and / or manufacturing errors and, above all, unless a slight deviation from the value, measure, shape or geometric reference to which? associated. For example, these terms, if associated with a value, preferably indicate a deviation of no more than 10% of the value itself.
Inoltre, quando usati, termini come ?primo?, ?secondo?, ?superiore?, ?inferiore?, ?principale? e ?secondario? non identificano necessariamente un ordine, una priorit? di relazione o posizione relativa, ma possono essere semplicemente utilizzati per pi? chiaramente distinguere tra loro differenti componenti. Also, when used, terms such as? First ?,? Second ?,? Superior ?,? Inferior ?,? Main? and? secondary? do they not necessarily identify an order, a priority? of relationship or relative position, but they can simply be used for more? clearly distinguish different components from each other.
Salvo diversamente specificato, come risulta dalle seguenti discussioni, si considera che termini come "trattamento", "informatica", "determinazione", "calcolo", o simili, si riferiscono all'azione e/o processi di un computer o simile dispositivo di calcolo elettronico che manipola e/o trasforma dati rappresentati come fisici, quali grandezze elettroniche di registri di un sistema informatico e/o memorie in, altri dati similmente rappresentati come quantit? fisiche all'interno di sistemi informatici, registri o altri dispositivi di memorizzazione, trasmissione o di visualizzazione di informazioni. Unless otherwise specified, as reflected in the following discussions, terms such as "processing", "computing", "determination", "computation", or the like, are deemed to refer to the action and / or processes of a computer or similar device electronic computation that manipulates and / or transforms data represented as physical, such as electronic quantities of registers of a computer system and / or memories into, other data similarly represented as quantities? physical in computer systems, registers or other devices for storing, transmitting or displaying information.
Le misurazioni e i dati riportati nel presente testo sono da considerarsi, salvo diversamente indicato, come effettuati in Atmosfera Standard Internazionale ICAO (ISO 2533:1975). The measurements and data reported in this text are to be considered, unless otherwise indicated, as carried out in the ICAO International Standard Atmosphere (ISO 2533: 1975).
Viene qui descritta una diluizione colloidale 1 per uso topico e cutaneo comprendente un composto con azione idratante e lubrificante 2, un composto con azione antiossidante ed antibatterica 3, un composto con azione idratante 4 solubile in acqua, un conservante naturale 5, un conservante 6, un composto con azione correttrice 7 del pH della diluizione (oppure ? un conservante anche?esso?), un conservante 8 ed acqua 9. Described here is a colloidal dilution 1 for topical and cutaneous use comprising a compound with moisturizing and lubricating action 2, a compound with antioxidant and antibacterial action 3, a compound with moisturizing action 4 soluble in water, a natural preservative 5, a preservative 6, a compound with corrective action 7 of the pH of the dilution (or? a preservative too? it?), a preservative 8 and water 9.
Essa pu? essere usata per scopi alimentari, integratori alimentari, scopi curativi o altro. It can? be used for food purposes, dietary supplements, curative or other purposes.
Viene qui descritta una diluizione colloidale 1 per uso topico e cutaneo comprendente acido ialuronico 2, metilsulfonilmetano 3, glicerolo 4, sodio citrato 5, metile p-ossibenzoato 6, acido citrico monoidrato 7, potassio sorbato 8 ed acqua 9. A colloidal dilution 1 for topical and cutaneous use is described herein comprising hyaluronic acid 2, methylsulfonylmethane 3, glycerol 4, sodium citrate 5, methyl p-oxybenzoate 6, citric acid monohydrate 7, potassium sorbate 8 and water 9.
Preferibilmente detto acido ialuronico 2 risulta compreso in una percentuale in peso compresa tra lo 0,01% e lo 0.2%. Preferably said hyaluronic acid 2 is comprised in a weight percentage comprised between 0.01% and 0.2%.
Ancora pi? preferibilmente detto acido ialuronico 2 risulta compreso in una percentuale in peso compresa tra lo 0,05% e lo 0.1%. Even more? preferably said hyaluronic acid 2 is comprised in a weight percentage comprised between 0.05% and 0.1%.
Nella forma di realizzazione preferita dell?invenzione la percentuale in peso di detto acido ialuronico 2 risulta pari allo 0,08%. In the preferred embodiment of the invention, the percentage by weight of said hyaluronic acid 2 is equal to 0.08%.
Preferibilmente detto metilsulfonilmetano 3 risulta compreso in una percentuale in peso compresa tra lo 0,01% e lo 0,3%. Preferably said methylsulfonylmethane 3 is comprised in a weight percentage comprised between 0.01% and 0.3%.
Ancora pi? preferibilmente detto metilsulfonilmetano 3 risulta compreso in una percentuale in peso compresa tra lo 0,05% e lo 0,15%. Even more? preferably said methylsulfonylmethane 3 is comprised in a weight percentage comprised between 0.05% and 0.15%.
Nella forma di realizzazione preferita dell?invenzione la percentuale in peso di detto metilsulfonilmetano 3 risulta pari allo 0,1%. In the preferred embodiment of the invention, the percentage by weight of said methylsulfonylmethane 3 is equal to 0.1%.
Preferibilmente detto glicerolo 4 risulta compreso in una percentuale in peso compresa tra il 10% e il 30%. Preferably said glycerol 4 is comprised in a weight percentage comprised between 10% and 30%.
Ancora pi? preferibilmente detto glicerolo 4 risulta compreso in una percentuale in peso compresa tra il 17% e il 23%. Even more? preferably said glycerol 4 is comprised in a weight percentage comprised between 17% and 23%.
Nella forma di realizzazione preferita dell?invenzione la percentuale in peso di detto glicerolo 4 risulta pari al 20%. In the preferred embodiment of the invention, the weight percentage of said glycerol 4 is equal to 20%.
Preferibilmente detto sodio citrato 5 risulta compreso in una percentuale in peso compresa tra lo 0,5% ed il 5%. Preferably said sodium citrate 5 is comprised in a weight percentage comprised between 0.5% and 5%.
Ancora pi? preferibilmente detto sodio citrato 5 risulta compreso in una percentuale in peso compresa tra l?1,5% ed il 2,5%. Even more? preferably said sodium citrate 5 is comprised in a weight percentage comprised between 1.5% and 2.5%.
Nella forma di realizzazione preferita dell?invenzione la percentuale in peso di detto sodio citrato 5 risulta pari al 2%. In the preferred embodiment of the invention, the percentage by weight of said sodium citrate 5 is equal to 2%.
Preferibilmente detto metile p-ossibenzoato 6 risulta compreso in una percentuale in peso compresa tra lo 0,01% e lo 0,5%. Preferably said methyl p-oxybenzoate 6 is comprised in a weight percentage comprised between 0.01% and 0.5%.
Ancora pi? preferibilmente detto metile p-ossibenzoato 6 risulta compreso in una percentuale in peso compresa tra lo 0,05% e lo 0,2%. Even more? preferably said methyl p-oxybenzoate 6 is comprised in a weight percentage comprised between 0.05% and 0.2%.
Nella forma di realizzazione preferita dell?invenzione la percentuale in peso di detto metile p-ossibenzoato 6 risulta pari allo 0,1%. In the preferred embodiment of the invention, the percentage by weight of said methyl p-oxybenzoate 6 is equal to 0.1%.
Preferibilmente detto acido citrico monoidrato 7 risulta compreso in una percentuale in peso compresa tra lo 0,1% e 5%. Preferably said citric acid monohydrate 7 is comprised in a weight percentage comprised between 0.1% and 5%.
Ancora pi? preferibilmente detto acido citrico monoidrato 7 risulta compreso in una percentuale in peso compresa tra l?1% ed il 2%. Even more? preferably said citric acid monohydrate 7 is comprised in a weight percentage comprised between 1% and 2%.
Nella forma di realizzazione preferita dell?invenzione la percentuale in peso di detto acido citrico monoidrato 7 risulta pari a 1,5%. In the preferred embodiment of the invention, the percentage by weight of said citric acid monohydrate 7 is equal to 1.5%.
Preferibilmente detto potassio sorbato 8 risulta compreso in una percentuale in peso compresa tra lo 0,01% e l?1%. Preferably said potassium sorbate 8 is comprised in a weight percentage comprised between 0.01% and 1%.
Ancora pi? preferibilmente detto potassio sorbato 8 risulta compreso in una percentuale in peso compresa tra lo 0,05% e lo 0,5%. Even more? preferably said potassium sorbate 8 is comprised in a weight percentage comprised between 0.05% and 0.5%.
Nella forma di realizzazione preferita dell?invenzione la percentuale in peso di detto potassio sorbato 8 risulta pari allo 0,1%. In the preferred embodiment of the invention, the percentage by weight of said potassium sorbate 8 is equal to 0.1%.
In ogni forma di realizzazione della presente invenzione detta acqua 9 viene utilizzata ed aggiunta alla composizione formante detta diluizione colloidale 1 fino a raggiungere la quantit? desiderata di diluizione colloidale 1 stessa. In each embodiment of the present invention, said water 9 is used and added to the composition forming said colloidal dilution 1 until the quantity? desired colloidal dilution 1 itself.
In una forma di realizzazione della presente invenzione detta acqua 9 ? una acqua 9 scelta tra acqua alcalina, acqua ionizzata o acqua ozonizzata. In an embodiment of the present invention said water 9? a water 9 chosen from alkaline water, ionized water or ozonated water.
In una forma di realizzazione alternativa della presente invenzione detta acqua 9 ? una qualsiasi combinazione di acqua alcalina, acqua ionizzata e acqua ozonizzata. In an alternative embodiment of the present invention said water 9? any combination of alkaline water, ionized water and ozonated water.
Ogni altra acqua 9 che sia atta ad essere usata come diluente o solvente per la diluizione colloidale 1 della presente invenzione pu? essere in questo contesto utilizzata, come ad esempio acqua trattata, acqua microfiltrata, acqua purificata etc. Any other water 9 which is suitable for use as a diluent or solvent for the colloidal dilution 1 of the present invention can be used as a diluent or solvent for the colloidal dilution 1 of the present invention. be used in this context, such as treated water, microfiltered water, purified water etc.
Risulta inoltre compreso nel concetto inventivo della presente invenzione ogni preparato medicinale 10 comprendente detta diluizione colloidale 1 per uso topico e cutaneo; ad esempio sono oggetto della presente invenzione preparati medicinali 10 in forma di prodotto spray. Furthermore, each medicinal preparation 10 comprising said colloidal dilution 1 for topical and cutaneous use is included in the inventive concept of the present invention; for example, medicinal preparations 10 in the form of a spray product are the object of the present invention.
Vantaggiosamente detta diluizione colloidale 1 pu? agire, grazie alla azione combinata dei suoi principi attivi, e nello specifico grazie alla presenza di acido ialuronico 2 e metilsulfonilmetano 3, da idratante cutaneo, antiet?, antirughe, coadiuvante nei problemi legati a secchezza della pelle, prurito, rossore, bruciore; la stessa diluizione colloidale 1 rende la pelle turgida e liscia, distende le piccole rughe. Grazie al film idratante e protettivo che detta diluizione colloidale 1 forma con la saliva, si deposita sulle mucose infiammate di bocca e faringe, favorendo il processo di guarigione delle mucose ed ? indicato in tutti i casi di mucosa orale infiammata, mal di gola, tosse secca, difficolt? nella deglutizione; inoltre grazie alla sua azione barriera riduce la flogosi delle corde vocali, ne migliora le propriet? viscoelastiche e riduce raucedine e disfonia. Advantageously, said colloidal dilution 1 can? act, thanks to the combined action of its active ingredients, and specifically thanks to the presence of hyaluronic acid 2 and methylsulfonylmethane 3, as a skin moisturizer, anti-aging, anti-wrinkle, adjuvant in problems related to dry skin, itching, redness, burning; the same colloidal dilution 1 makes the skin turgid and smooth, relaxes small wrinkles. Thanks to the moisturizing and protective film that said colloidal dilution 1 forms with saliva, it is deposited on the inflamed mucous membranes of the mouth and pharynx, favoring the healing process of the mucous membranes and? indicated in all cases of inflamed oral mucosa, sore throat, dry cough, difficulty? in swallowing; moreover, thanks to its barrier action it reduces the inflammation of the vocal cords, improves its properties? viscoelastic and reduces hoarseness and dysphonia.
L?invenzione ? suscettibile di varianti rientranti nell'ambito del concetto inventivo definito dalle rivendicazioni. The invention? susceptible of variants falling within the scope of the inventive concept defined by the claims.
In tale ambito tutti i dettagli sono sostituibili da elementi equivalenti ed i materiali, le forme e le dimensioni possono essere qualsiasi. In this context, all the details can be replaced by equivalent elements and the materials, shapes and dimensions can be any.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000003733A IT202000003733A1 (en) | 2020-02-24 | 2020-02-24 | COLLOIDAL DILUTION FOR TOPICAL AND ORAL USE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000003733A IT202000003733A1 (en) | 2020-02-24 | 2020-02-24 | COLLOIDAL DILUTION FOR TOPICAL AND ORAL USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT202000003733A1 true IT202000003733A1 (en) | 2021-08-24 |
Family
ID=70918792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102020000003733A IT202000003733A1 (en) | 2020-02-24 | 2020-02-24 | COLLOIDAL DILUTION FOR TOPICAL AND ORAL USE |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT202000003733A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1444984A1 (en) * | 2003-02-06 | 2004-08-11 | B.S.D. BIO SCIENCE DEVELOPMENT SNC Di OMINI C. & ZUCCARI G. | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes |
| WO2007144613A1 (en) * | 2006-06-13 | 2007-12-21 | Sinclair Pharmaceuticals Limited | Antimicrobial composition |
| US20090117061A1 (en) * | 2007-10-01 | 2009-05-07 | Gross Dennis F | Skin care products containing multiple enhancers |
| WO2019077521A1 (en) * | 2017-10-17 | 2019-04-25 | Alfakjn S.R.L. | Liquid composition for use and as an anti-inflammatory |
-
2020
- 2020-02-24 IT IT102020000003733A patent/IT202000003733A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1444984A1 (en) * | 2003-02-06 | 2004-08-11 | B.S.D. BIO SCIENCE DEVELOPMENT SNC Di OMINI C. & ZUCCARI G. | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes |
| WO2007144613A1 (en) * | 2006-06-13 | 2007-12-21 | Sinclair Pharmaceuticals Limited | Antimicrobial composition |
| US20090117061A1 (en) * | 2007-10-01 | 2009-05-07 | Gross Dennis F | Skin care products containing multiple enhancers |
| WO2019077521A1 (en) * | 2017-10-17 | 2019-04-25 | Alfakjn S.R.L. | Liquid composition for use and as an anti-inflammatory |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ulrey et al. | Cranberry proanthocyanidins have anti-biofilm properties against Pseudomonas aeruginosa | |
| Scheibler et al. | Use of nystatin and chlorhexidine in oral medicine: Properties, indications and pitfalls with focus on geriatric patients | |
| KR101845472B1 (en) | Topical compositions for preserving or restoring the integrity of mucosae | |
| Arsić et al. | Estimation of dermatological application of creams with St. John’s Wort oil extracts | |
| AU2014385792B2 (en) | Composition and method for enhancing wound healing | |
| ES2560953T3 (en) | Combined plant extracts for use in the treatment of microbial infections | |
| JP2006274245A (en) | Compound selected from sulfated cellulose and its salt and dermatitis therapeutic agent | |
| Castillo Pedraza et al. | Modulation of lipoteichoic acids and exopolysaccharides prevents Streptococcus mutans biofilm accumulation | |
| ITMI20102009A1 (en) | COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ULCERS OF VARIOUS ORIGIN | |
| Sharma et al. | Envisaging antifungal potential of histatin 5: a physiological salivary peptide | |
| Sparavigna et al. | Effects of a novel nail lacquer based on hydroxypropyl-chitosan (HPCH) in subjects with fingernail onychoschizia | |
| IT202000003733A1 (en) | COLLOIDAL DILUTION FOR TOPICAL AND ORAL USE | |
| Rajasekar et al. | Tannic acid alleviates experimental pulmonary fibrosis in mice by inhibiting inflammatory response and fibrotic process | |
| Enax et al. | Overview on adjunct ingredients used in hydroxyapatite-based oral care products | |
| RU2604576C1 (en) | Pharmaceutical composition for treating infectious-inflammatory diseases of local application and method of its production and application | |
| Welte | Community-acquired pneumonia: a disease of the elderly | |
| TW201427714A (en) | Ointment for application to mucous membrane | |
| Peng et al. | Amphotericin B-and levofloxacin-loaded chitosan films for potential use in antimicrobial wound dressings: Analytical method development and its application | |
| ITUB20154846A1 (en) | Oral composition in the form of a gel comprising chitosan, a high-methoxylated pectin, a sugary substance, L-carnitine and N-acetylcysteine | |
| Sasagawa et al. | Matcha Green Tea Exhibits Bactericidal Activity against Streptococcus pneumoniae and Inhibits Functional Pneumolysin | |
| EP1764104A1 (en) | Wound healing pharmaceutical composition comprising sucralfate, aluminium acetate and vitamins | |
| Belvedere et al. | The Protecting Activity of RIPACUT®: A New Therapeutic Approach Preserving Epithelial Health Based on the Combination of Iceland Lichen Extract, Silver Salt, and Sodium Hyaluronate | |
| MD3619F1 (en) | Nasal remedy possessing vasoconstrictive and anti-edematous action | |
| Upadya et al. | Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin | |
| Dhimmar et al. | Newfangled Topical Film-Forming Solution for Facilitated Antifungal Therapy: Design, Development, Characterization, and In Vitro Evaluation |